The fall in the company's stock price has more than discounted the negative impact of litigation and muted growth in the US business on the company's earnings.
The long-term growth drivers for Glenmark appear intact. A strong presence in the US, Asia, Africa and CIS, steady product launches, and a healthy pipeline of niche products are promising factors for the company. The stock is trading at a significant discount to its frontline peers.
Considering the growth prospects of the company's base business, the stock is trading at an attractive price to earnings multiple of 16. Since the growth of the company's core generics business remains promising, the current weakness in the stock offers a buying opportunity for investors scouting the mid-cap segment.
Posts
![[ Registered ]](http://www.diarist.net/registry/button.gif){kind=small}
No comments:
Post a Comment